UroGen Pharma Ltd.
URGN
$18.44
-$0.35-1.86%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 54.03% | 9.04% | 10.83% | 7.84% | 4.40% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 54.03% | 9.04% | 10.83% | 7.84% | 4.40% |
| Cost of Revenue | 33.10% | 33.63% | 59.26% | 34.84% | 8.09% |
| Gross Profit | 56.37% | 6.39% | 5.33% | 5.11% | 4.00% |
| SG&A Expenses | 9.43% | 29.86% | 43.73% | 28.09% | 46.46% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.81% | 28.35% | 37.70% | 28.41% | 39.81% |
| Operating Income | 33.53% | -56.09% | -60.41% | -43.41% | -96.85% |
| Income Before Tax | 23.59% | -45.88% | -46.64% | -34.81% | -57.31% |
| Income Tax Expenses | -110.38% | -1,258.24% | 2,571.05% | 625.93% | -31.27% |
| Earnings from Continuing Operations | 29.72% | -40.87% | -49.51% | -35.80% | -44.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 29.72% | -40.87% | -49.51% | -35.80% | -44.19% |
| EBIT | 33.53% | -56.09% | -60.41% | -43.41% | -96.85% |
| EBITDA | 33.64% | -51.08% | -60.53% | -43.82% | -98.97% |
| EPS Basic | 32.86% | -37.11% | -26.85% | -6.12% | -10.84% |
| Normalized Basic EPS | 29.23% | -41.99% | -24.39% | -5.35% | -24.75% |
| EPS Diluted | 32.86% | -37.11% | -26.85% | -6.12% | -10.84% |
| Normalized Diluted EPS | 29.23% | -41.99% | -24.39% | -5.35% | -24.75% |
| Average Basic Shares Outstanding | 4.68% | 2.73% | 17.87% | 27.96% | 30.09% |
| Average Diluted Shares Outstanding | 4.68% | 2.73% | 17.87% | 27.96% | 30.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |